| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 1999;15:490-495
© 1999 Elsevier Science NL
a Cardiothoracic Surgery Service, La Timone Children's Hospital, Boulevard Jean Moulin-13385, Marseilles Cedex 05, France
b Department of Anesthesia and Intensive Care, La Timone Children's Hospital, Boulevard Jean Moulin-13385, Marseilles Cedex 05, France
Received 26 May 1998; received in revised form 13 January 1999; accepted 1 February 1999.
Corresponding author. Tel.: +33-4-9138-6676; fax: +33-4-9147-8170; e-mail: dmetras@ap-hm
Objectives: Pulmonary infections, and particularly cytomegalovirus (CMV) infections, are a major cause of morbidity after lung transplantation. We report here our results in 49 pediatric lung transplantations. Methods: Between may 1988 and 1997, we have done 49 lung transplantations in 42 children (en bloc double lung transplantation (DLT):10, HLTx:7, sequential bilateral sequential-lung transplantation (BSLT):31, single-lung transplantation (SLT): 1). In seven, it was a retransplantation. Among these, 34 were cystic fibrosis (CF) patients, all with multiresistant organisms (Pseudomonas aeruginosa, Burkholderia cepacia, Achromobacter xylososydans, Staphyloccus aureus). All patients were treated with multiantibiotic prophylaxy adapted to the preoperative cultures. Donor-recipient CMV matching was possible in only 31 cases. CMV prophylaxy and immunosuppression protocols have evolved with time, with a current protocol of IV Gancyclovir prophylaxy for 3 months and triple drug immunosuppression without post-operative rabbit anti-thymocyte globulin (RATG) induction. There was no perioperative mortality in the primary transplantations and three early deaths in the whole group (6.1%). Results: Only five patients had no pulmonary infection. The patients presented 3.2 infection episodes per year, 75% localized on the lungs, 41% during the first 3 months. Among the 13 deaths in the 1st year, 10 were directly related to infection, 60% due to CMV. After the 1st year, in all patients dying of pulmonary dysfunction or obliterative bronchiolitis (OB), bacterial infections were associated. There was no serious fungal infection. Actuarial survival at 3 months, 1, 3, 5 years were 85, 65.7, 47.5 and 28.5%, respectively. There was a significant difference in 3 year survival between patients receiving CMV negative organs (40%) and CMV positive organs (17%). Conclusion: In our experience, as in other's, pulmonary infection risk is important in lung transplantation. Bacterial infections were mainly an aggravating factor of secondary pulmonary dysfunction or OB, and were not the primary cause of death. CMV infections have been very severe and lead us, despite the scarcity of donors, to avoid positive donors in negative recipients, this leads to disastrous mid-term results in our experience, despite prophylaxis.
Key Words: Pediatric • Lung • Transplantation • Pulmonary • Infections
This article has been cited by other articles:
|
|
 |
|
  B. Bech, T. Pressler, M. Iversen, J. Carlsen, N. Milman, K. Eliasen, M. Perko, and H. Arendrup Long-term outcome of lung transplantation for cystic fibrosis -- Danish results Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1180 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. ARIS, J. C. ROUTH, J. J. LIPUMA, D. G. HEATH, and P. H. GILLIGAN Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex . Survival Linked to Genomovar Type Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2102 - 2106. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
